Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12$

Name of	entity	
NETLIN	NKZ LIMITED	
ABN 55 141 50	09 426	
	e entity) give ASX the following	information.
	- All issues t complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	500,000 shares
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary fully paid Shares from exercise of 500,000 options

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Exercise at \$0.01 of 500,000 Unlisted Options expiring on or before 2 July 2020.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Option exercise
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6с	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

⁺ See chapter 19 for defined terms.

6е	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	500,000	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1 – 20,07	79,865
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	30 October 2019	
		N7 1	CI
0	N 1 1 ±1 6 11	Number	+Class
8	Number and *class of all *securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)	1,715,378,873	Fully paid ordinary shares
		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the securities in section 2 if applicable)	39,375,000	Unlisted Options exercisable at \$0.01 expiring on 2 July 2020.
		33,500,000	Unlisted Options exercisable at \$0.045 expiring on 1 Aug

⁺ See chapter 19 for defined terms.

2020.

2,500,000	Unlisted Options exercisable at \$0.06 expiring on 1 Aug 2020.
5,000,000	Unlisted Options exercisable at \$0.12 expiring on 1 Aug 2020.
10,000,000	Unlisted Options exercisable at \$0.30 expiring on 1 Aug 2020.
267,379	Unlisted Options exercisable at \$0.187 on or before 3 November 2020.
188,890	Unlisted Options exercisable at \$0.045 expiring on 31 Jan 2020.
5,000,000	Unlisted Options exercisable at \$0.30 expiring on 31 Jan 2020.
3,300,000	Unlisted Options exercisable at \$0.06 expiring on 1 Jan 2021.
3,300,000	Unlisted Options exercisable at \$0.12 expiring on 1 Jan 2021.
3,400,000	Unlisted Options exercisable at \$0.24 expiring on 1 Jan 2021.
26,000,000	Unlisted Options exercisable at \$0.02

⁺ See chapter 19 for defined terms.

	expiring on 2 Jul 2021.
2,250,000	Unlisted Options exercisable at \$0.045 expiring on 2 Jul 2021.
6,250,000	Unlisted Options exercisable at \$0.09 expiring on 2 Jul 2021.
5,000,000	Unlisted Options exercisable at \$0.15 expiring on 2 Jul 2021.
2,000,000	Unlisted Options exercisable at \$0.06 expiring on 1 Oct 2021.
2,000,000	Unlisted Options exercisable at \$0.12 expiring on 1 Oct 2021.
2,000,000	Unlisted Options exercisable at \$0.24 expiring on 1 Oct 2021.
2,000000	Unlisted Options exercisable at \$0.36 expiring on 1 Oct 2021.
25,000,000	Unlisted Options exercisable at \$0.02 expiring on 21 Dec 2021.
50,800,000	Unlisted Options exercisable at \$0.037 expiring on 31 Jan 2022.

⁺ See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
Part 2	? - Bonus issue or pro rat	a issue
11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of	N/A
20	acceptances or renunciations Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Despatch date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of securities (*tick one*)

(a) Securities described in Part 1. Fully paid ordinary shares only

⁺ See chapter 19 for defined terms.

(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
	securities
Entitie	s that have ticked box 34(a)
Additi	ional securities forming a new class of securities
Tick to docum	o indicate you are providing the information or ents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Entitie	es that have ticked box 34(b)
38	Number of securities for which †quotation is sought
39	Class of *securities for which quotation is sought
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend,

⁺ See chapter 19 for defined terms.

	distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)		

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

⁺ See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 31 October 2019

(Company Secretary)

Print name: Robert Lees

== == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,272,412,369	
Add the following:		
 Number of fully paid ordinary securities issued in that 12-month period under an exception in rule 7.2 Number of fully paid ordinary securities issued in that 12-month period with shareholder approval Number of partly paid ordinary securities that became fully paid in that 12-month period 	292,347,336 500,000 this Appendix 3B	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid ordinary securities cancelled during that 12-month period	-	
"A"	1,565,259,705	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	234,788,955	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
 Insert number of equity securities issued or agreed to be issued in that 12-month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A 	123,800,000 previous Appendix 3B 90,909,090 this Appendix 3B	
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	214,709,090	
Step 4: Subtract "C" from ["A" x 'placement capacity under rule 7.1	, - I	
Note: number must be same as shown in Step 2	234,788,955	
Subtract "C"	214,709,090	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	20,079,865	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"		
Step 4: Subtract "E" from ["A" x " placement capacity under rule 7.1 "A" x 0.10 Note: number must be same as shown in Step 2	-	
Subtract "E" Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E" Note: this is the remaining placement capacity under rule 7.1A		

⁺ See chapter 19 for defined terms.